244 related articles for article (PubMed ID: 31043708)
1. Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer.
Fletcher CE; Sulpice E; Combe S; Shibakawa A; Leach DA; Hamilton MP; Chrysostomou SL; Sharp A; Welti J; Yuan W; Dart DA; Knight E; Ning J; Francis JC; Kounatidou EE; Gaughan L; Swain A; Lupold SE; de Bono JS; McGuire SE; Gidrol X; Bevan CL
Oncogene; 2019 Jul; 38(28):5700-5724. PubMed ID: 31043708
[TBL] [Abstract][Full Text] [Related]
2. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
3. miR-103a-2-5p/miR-30c-1-3p inhibits the progression of prostate cancer resistance to androgen ablation therapy via targeting androgen receptor variant 7.
Chen W; Yao G; Zhou K
J Cell Biochem; 2019 Aug; 120(8):14055-14064. PubMed ID: 30963631
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.
Hoang DT; Iczkowski KA; Kilari D; See W; Nevalainen MT
Oncotarget; 2017 Jan; 8(2):3724-3745. PubMed ID: 27741508
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer.
Coarfa C; Fiskus W; Eedunuri VK; Rajapakshe K; Foley C; Chew SA; Shah SS; Geng C; Shou J; Mohamed JS; O'Malley BW; Mitsiades N
Oncogene; 2016 May; 35(18):2345-56. PubMed ID: 26364608
[TBL] [Abstract][Full Text] [Related]
6. Targeting androgen receptor (AR) with antiandrogen Enzalutamide increases prostate cancer cell invasion yet decreases bladder cancer cell invasion via differentially altering the AR/circRNA-ARC1/miR-125b-2-3p or miR-4736/PPARγ/MMP-9 signals.
Deng G; Wang R; Sun Y; Huang CP; Yeh S; You B; Feng C; Li G; Ma S; Chang C
Cell Death Differ; 2021 Jul; 28(7):2145-2159. PubMed ID: 34127806
[TBL] [Abstract][Full Text] [Related]
7. [miR-141-3p regulates the expression of androgen receptor by targeting its 3'UTR in prostate cancer LNCaP cells].
Wang C; Ouyang Y; Lu M; Wei J; Zhang H
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 Jun; 31(6):736-9. PubMed ID: 26062412
[TBL] [Abstract][Full Text] [Related]
8. Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor.
Coleman DJ; Van Hook K; King CJ; Schwartzman J; Lisac R; Urrutia J; Sehrawat A; Woodward J; Wang NJ; Gulati R; Thomas GV; Beer TM; Gleave M; Korkola JE; Gao L; Heiser LM; Alumkal JJ
Oncotarget; 2016 Jun; 7(26):40690-40703. PubMed ID: 27276681
[TBL] [Abstract][Full Text] [Related]
9. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer.
Guerrero J; Alfaro IE; Gómez F; Protter AA; Bernales S
Prostate; 2013 Sep; 73(12):1291-305. PubMed ID: 23765603
[TBL] [Abstract][Full Text] [Related]
10. Triptolide Inhibits the AR Signaling Pathway to Suppress the Proliferation of Enzalutamide Resistant Prostate Cancer Cells.
Han Y; Huang W; Liu J; Liu D; Cui Y; Huang R; Yan J; Lei M
Theranostics; 2017; 7(7):1914-1927. PubMed ID: 28638477
[TBL] [Abstract][Full Text] [Related]
11. Role of BioResponse 3,3'-Diindolylmethane in the Treatment of Human Prostate Cancer: Clinical Experience.
Li Y; Sarkar FH
Med Princ Pract; 2016; 25 Suppl 2(Suppl 2):11-7. PubMed ID: 26501150
[TBL] [Abstract][Full Text] [Related]
12. MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A.
Sun T; Wang X; He HH; Sweeney CJ; Liu SX; Brown M; Balk S; Lee GS; Kantoff PW
Oncogene; 2014 May; 33(21):2790-800. PubMed ID: 23770851
[TBL] [Abstract][Full Text] [Related]
13. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR
Wu Z; Wang K; Yang Z; Pascal LE; Nelson JB; Takubo K; Wipf P; Wang Z
Prostate; 2020 Mar; 80(4):319-328. PubMed ID: 31868960
[TBL] [Abstract][Full Text] [Related]
14. Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer.
Qi W; Morales C; Cooke LS; Johnson B; Somer B; Mahadevan D
Oncotarget; 2015 Dec; 6(39):41976-87. PubMed ID: 26506516
[TBL] [Abstract][Full Text] [Related]
15. Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells.
Östling P; Leivonen SK; Aakula A; Kohonen P; Mäkelä R; Hagman Z; Edsjö A; Kangaspeska S; Edgren H; Nicorici D; Bjartell A; Ceder Y; Perälä M; Kallioniemi O
Cancer Res; 2011 Mar; 71(5):1956-67. PubMed ID: 21343391
[TBL] [Abstract][Full Text] [Related]
16. Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells.
Kranzbühler B; Salemi S; Mortezavi A; Sulser T; Eberli D
Prostate; 2019 Feb; 79(2):206-214. PubMed ID: 30345525
[TBL] [Abstract][Full Text] [Related]
17. Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
Abudurexiti M; Zhu W; Wang Y; Wang J; Xu W; Huang Y; Zhu Y; Shi G; Zhang H; Zhu Y; Shen Y; Dai B; Wan F; Lin G; Ye D
Prostate; 2020 Sep; 80(12):950-961. PubMed ID: 32648618
[TBL] [Abstract][Full Text] [Related]
18. Multifaceted Function of MicroRNA-299-3p Fosters an Antitumor Environment Through Modulation of Androgen Receptor and VEGFA Signaling Pathways in Prostate Cancer.
Ganapathy K; Staklinski S; Hasan MF; Ottman R; Andl T; Berglund AE; Park JY; Chakrabarti R
Sci Rep; 2020 Mar; 10(1):5167. PubMed ID: 32198489
[TBL] [Abstract][Full Text] [Related]
19. Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer.
Jalava SE; Urbanucci A; Latonen L; Waltering KK; Sahu B; Jänne OA; Seppälä J; Lähdesmäki H; Tammela TL; Visakorpi T
Oncogene; 2012 Oct; 31(41):4460-71. PubMed ID: 22266859
[TBL] [Abstract][Full Text] [Related]
20. Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer.
Schalken J; Fitzpatrick JM
BJU Int; 2016 Feb; 117(2):215-25. PubMed ID: 25818596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]